107 related articles for article (PubMed ID: 7763310)
61. A novel bis-indole destabilizes microtubules and displays potent in vitro and in vivo antitumor activity in prostate cancer.
Ahn S; Hwang DJ; Barrett CM; Yang J; Duke CB; Miller DD; Dalton JT
Cancer Chemother Pharmacol; 2011 Feb; 67(2):293-304. PubMed ID: 20383708
[TBL] [Abstract][Full Text] [Related]
62. Design, Synthesis, and Biological Evaluation of 1-Methyl-1,4-dihydroindeno[1,2-c]pyrazole Analogues as Potential Anticancer Agents Targeting Tubulin Colchicine Binding Site.
Liu YN; Wang JJ; Ji YT; Zhao GD; Tang LQ; Zhang CM; Guo XL; Liu ZP
J Med Chem; 2016 Jun; 59(11):5341-55. PubMed ID: 27172319
[TBL] [Abstract][Full Text] [Related]
63. 2-aroylindoles, a novel class of potent, orally active small molecule tubulin inhibitors.
Beckers T; Reissmann T; Schmidt M; Burger AM; Fiebig HH; Vanhoefer U; Pongratz H; Hufsky H; Hockemeyer J; Frieser M; Mahboobi S
Cancer Res; 2002 Jun; 62(11):3113-9. PubMed ID: 12036922
[TBL] [Abstract][Full Text] [Related]
64. 1,2,3-triazole tethered Indole-3-glyoxamide derivatives as multiple inhibitors of 5-LOX, COX-2 & tubulin: Their anti-proliferative & anti-inflammatory activity.
Naaz F; Preeti Pallavi MC; Shafi S; Mulakayala N; Shahar Yar M; Sampath Kumar HM
Bioorg Chem; 2018 Dec; 81():1-20. PubMed ID: 30081353
[TBL] [Abstract][Full Text] [Related]
65. Synthesis, biological evaluation and molecular docking studies of aminochalcone derivatives as potential anticancer agents by targeting tubulin colchicine binding site.
Wang G; Peng Z; Zhang J; Qiu J; Xie Z; Gong Z
Bioorg Chem; 2018 Aug; 78():332-340. PubMed ID: 29627654
[TBL] [Abstract][Full Text] [Related]
66. Structure-activity relationship for DNA topoisomerase II-induced DNA cleavage by azatoxin analogues.
Madalengoitia JS; Tepe JJ; Werbovetz KA; Lehnert EK; Macdonald TL
Bioorg Med Chem; 1997 Sep; 5(9):1807-15. PubMed ID: 9354236
[TBL] [Abstract][Full Text] [Related]
67. A rational design strategy of the novel topoisomerase II inhibitors for the synthesis of the 4-O-(2-pyrazinecarboxylic)-4'-demethylepipodophyllotoxin with antitumor activity by diminishing the relaxation reaction of topoisomerase II-DNA decatenation.
Zhao W; Chen L; Li HM; Wang DJ; Li DS; Chen T; Yuan ZP; Tang YJ
Bioorg Med Chem; 2014 Jun; 22(11):2998-3007. PubMed ID: 24775914
[TBL] [Abstract][Full Text] [Related]
68. Design and biological evaluation of novel tubulin inhibitors as antimitotic agents using a pharmacophore binding model with tubulin.
Kim DY; Kim KH; Kim ND; Lee KY; Han CK; Yoon JH; Moon SK; Lee SS; Seong BL
J Med Chem; 2006 Sep; 49(19):5664-70. PubMed ID: 16970393
[TBL] [Abstract][Full Text] [Related]
69. Targeting DNA topoisomerase II in cancer chemotherapy.
Nitiss JL
Nat Rev Cancer; 2009 May; 9(5):338-50. PubMed ID: 19377506
[TBL] [Abstract][Full Text] [Related]
70. 2-amino and 2'-aminocombretastatin derivatives as potent antimitotic agents.
Chang JY; Yang MF; Chang CY; Chen CM; Kuo CC; Liou JP
J Med Chem; 2006 Oct; 49(21):6412-5. PubMed ID: 17034147
[TBL] [Abstract][Full Text] [Related]
71. Intoplicine (RP 60475) and its derivatives, a new class of antitumor agents inhibiting both topoisomerase I and II activities.
Riou JF; Fossé P; Nguyen CH; Larsen AK; Bissery MC; Grondard L; Saucier JM; Bisagni E; Lavelle F
Cancer Res; 1993 Dec; 53(24):5987-93. PubMed ID: 8261412
[TBL] [Abstract][Full Text] [Related]
72. [Molecular determinants of response to topoisomerase II inhibitors].
Lansiaux A; Pourquier P
Bull Cancer; 2011 Nov; 98(11):1299-310. PubMed ID: 22023806
[TBL] [Abstract][Full Text] [Related]
73. Design, synthesis, and biological evaluation of novel combretastatin A-4 thio derivatives as microtubule targeting agents.
Stefański T; Mikstacka R; Kurczab R; Dutkiewicz Z; Kucińska M; Murias M; Zielińska-Przyjemska M; Cichocki M; Teubert A; Kaczmarek M; Hogendorf A; Sobiak S
Eur J Med Chem; 2018 Jan; 144():797-816. PubMed ID: 29291446
[TBL] [Abstract][Full Text] [Related]
74. Structure-based virtual screening of novel tubulin inhibitors and their characterization as anti-mitotic agents.
Kim ND; Park ES; Kim YH; Moon SK; Lee SS; Ahn SK; Yu DY; No KT; Kim KH
Bioorg Med Chem; 2010 Oct; 18(19):7092-100. PubMed ID: 20810285
[TBL] [Abstract][Full Text] [Related]
75. A flow cytometry-based method for a high-throughput analysis of drug-stabilized topoisomerase II cleavage complexes in human cells.
de Campos-Nebel M; Palmitelli M; González-Cid M
Cytometry A; 2016 Sep; 89(9):852-60. PubMed ID: 27517472
[TBL] [Abstract][Full Text] [Related]
76. Phenanthriplatin Acts As a Covalent Poison of Topoisomerase II Cleavage Complexes.
Riddell IA; Agama K; Park GY; Pommier Y; Lippard SJ
ACS Chem Biol; 2016 Nov; 11(11):2996-3001. PubMed ID: 27648475
[TBL] [Abstract][Full Text] [Related]
77. Optimization of New Catalytic Topoisomerase II Inhibitors as an Anti-Cancer Therapy.
Matias-Barrios VM; Radaeva M; Ho CH; Lee J; Adomat H; Lallous N; Cherkasov A; Dong X
Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359577
[TBL] [Abstract][Full Text] [Related]
78. Identification of potent catalytic inhibitors of human DNA topoisomerase II by structure-based virtual screening.
Dong G; Wu Y; Sun Y; Liu N; Wu S; Zhang W; Sheng C
Medchemcomm; 2018 Jul; 9(7):1142-1146. PubMed ID: 30109001
[TBL] [Abstract][Full Text] [Related]
79. Discovery of New Catalytic Topoisomerase II Inhibitors for Anticancer Therapeutics.
Matias-Barrios VM; Radaeva M; Song Y; Alperstein Z; Lee AR; Schmitt V; Lee J; Ban F; Xie N; Qi J; Lallous N; Gleave ME; Cherkasov A; Dong X
Front Oncol; 2020; 10():633142. PubMed ID: 33598437
[TBL] [Abstract][Full Text] [Related]
80. Synthesis and biological evaluation of tetrademethyl isocolchicine derivatives as inhibitors of DNA topoisomerase action in vitro.
Bastow KF; Tatematsu H; Sun L; Fukushima Y; Lee KH
Bioorg Med Chem; 1993 Sep; 1(3):227-34. PubMed ID: 8081856
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
